Hantz Financial Services Inc. Acquires New Stake in Solventum Co. (NYSE:SOLV)

Hantz Financial Services Inc. bought a new stake in shares of Solventum Co. (NYSE:SOLV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 835 shares of the company’s stock, valued at approximately $44,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC purchased a new position in shares of Solventum in the first quarter valued at approximately $30,000. Richard W. Paul & Associates LLC purchased a new position in Solventum in the 2nd quarter valued at approximately $26,000. Family Firm Inc. acquired a new position in shares of Solventum in the second quarter worth $26,000. Partnership Wealth Management LLC purchased a new stake in shares of Solventum during the second quarter worth $26,000. Finally, CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Solventum in the second quarter valued at $27,000.

Solventum Stock Performance

SOLV stock opened at $64.11 on Tuesday. Solventum Co. has a fifty-two week low of $47.16 and a fifty-two week high of $96.05. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.31 and a quick ratio of 0.96. The stock’s 50 day simple moving average is $55.86.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, August 8th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.10. The company had revenue of $2.08 billion during the quarter, compared to analyst estimates of $2.05 billion. The business’s revenue for the quarter was up .2% on a year-over-year basis. Analysts forecast that Solventum Co. will post 6.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently commented on SOLV shares. Morgan Stanley lowered their target price on Solventum from $70.00 to $55.00 and set an “equal weight” rating for the company in a research note on Monday, July 15th. The Goldman Sachs Group upped their target price on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a research note on Monday, August 12th. Bank of America decreased their price target on shares of Solventum from $70.00 to $60.00 and set a “neutral” rating for the company in a research note on Tuesday, June 25th. Wells Fargo & Company dropped their price objective on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Finally, Argus assumed coverage on shares of Solventum in a research report on Monday, June 24th. They set a “hold” rating for the company. One analyst has rated the stock with a sell rating and five have issued a hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $58.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.